Bicara Responds to Rival Merus With Early Survival Data at #ASCO25
Following Merus’ splash last month with a “best-in-disease profile” for its head and neck cancer bispecific, Bicara touted positive results for its monocolonal antibody, but analysts say Merus still has the upper hand.
Bicara Responds to Rival Merus With Early Survival Data at #ASCO25 Read More »
